Appendix Table A3.
Distribution of Stereoacuity and Change in Stereoacuity from Baseline by Treatment Group.
| Baseline | 4 weeksa | 8 weeksa | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||
| Binocular Treatment |
Continued Spectacles |
Binocular Treatment |
Continued Spectacles |
Binocular Treatment |
Continued Spectacles |
|||||||
|
|
||||||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
|
| ||||||||||||
| Per Group(N) | 92 | 90 | 85 | 84 | 85 | 84 | ||||||
|
| ||||||||||||
| Stereoacuity (Seconds of Arc) b | ||||||||||||
| Missing/Not done | 3 | 3% | 8 | 9% | 6 | 7% | 8 | 10% | 5 | 6% | 9 | 11% |
| Nil | 27 | 29% | 22 | 24% | 24 | 28% | 21 | 25% | 24 | 28% | 18 | 21% |
| 2000 | 13 | 14% | 11 | 12% | 8 | 9% | 10 | 12% | 10 | 12% | 6 | 7% |
| 800 | 13 | 14% | 10 | 11% | 13 | 15% | 7 | 8% | 10 | 12% | 15 | 18% |
| 400 | 11 | 12% | 19 | 21% | 10 | 12% | 15 | 18% | 9 | 11% | 12 | 14% |
| 200 | 13 | 14% | 12 | 13% | 9 | 11% | 9 | 11% | 12 | 14% | 9 | 11% |
| 100 | 9 | 10% | 5 | 6% | 10 | 12% | 6 | 7% | 10 | 12% | 7 | 8% |
| 60 | 1 | 1% | 2 | 2% | 3 | 4% | 5 | 6% | 2 | 2% | 3 | 4% |
| 40 | 2 | 2% | 1 | 1% | 2 | 2% | 3 | 4% | 3 | 4% | 5 | 6% |
| Median (Range) | 800 (40 to Nil) | 800 (40 to Nil) | 800 (40 to Nil) | 400–800 (40 to Nil) | 800 (40 to Nil) | 800 (40 to Nil) | ||||||
|
| ||||||||||||
| Change in Level of Stereoacuity from Baseline c | ||||||||||||
| > 2 Levels Worse | 11 | 14% | 8 | 11% | 7 | 9% | 3 | 4% | ||||
| Within 1 Level | 56 | 72% | 57 | 78% | 61 | 78% | 54 | 75% | ||||
| > 2 Levels Better | 11 | 14% | 8 | 11% | 10 | 13% | 15 | 21% | ||||
a
Limited to follow-up visits completed within the pre-specified analysis windows.
b
Results of the Randot Butterfly stereoacuity test were analyzed as 2000 seconds of arc (if correct response) or nil (if incorrect response) in the presence of an incorrect response on the 800 seconds of arc level of the Randot Preschool stereoacuity test.
c
The exact Wilcoxon rank-sum test was used to compare the change in stereoacuity from baseline to the 4-week visit (Bonferroni-adjusted P > .99) and to the 8-week visit (Bonferroni-adjusted P > .99) between the treatment groups.